(Q48125845)

8 February 2018

title

Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. (English)

1 reference

8 February 2018

high-performance liquid chromatography

1 reference

1 reference

4

Greenblatt DJ

1 reference

8 February 2018

Lisa L. von Moltke

series ordinal

3

object named as

von Moltke LL

1 reference

8 February 2018

author name string

Granda BW

series ordinal

1

1 reference

8 February 2018

Giancarlo GM

series ordinal

2

1 reference

8 February 2018

publication date

1 November 1998

1 reference

8 February 2018

Journal of Pharmacological and Toxicological Methods

published in

1 reference

8 February 2018

volume

40

1 reference

8 February 2018

page(s)

235-239

1 reference

8 February 2018

issue

4

1 reference

8 February 2018

describes a project that uses

high-performance liquid chromatography

1 reference

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

inferred from title

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8719%2899%2900013-1

7 January 2021

10.1016/S1056-8719(99)00013-1

Identifiers

DOI

1 reference

8 February 2018

PubMed ID

10465159

1 reference

8 February 2018